Supplementation with CalGo® Salmon Bone Complex Im-Proves Femoral Neck and Preserves Lumbar Spine Bone Min-Eral Density: 2-Year Randomized Placebo-Controlled Trial
Preprint
- 10 September 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Osteopenia predisposes to osteoporosis and fracture, especially at the femoral neck and spine. Conventional calcium supplements offer modest benefit with tolerability limits. CalGo®, a salmon bone complex (calcium hydroxyapatite, colla-gen, trace minerals), may support skeletal health. We evaluated its efficacy and safety in postmenopausal women with osteopenia. Methods: In a 24-month, randomized, dou-ble-blind, placebo-controlled trial, 80 women aged 50–80 years with DXA-confirmed fem-oral-neck osteopenia were assigned to daily CalGo® (n=40) or placebo (n=40). The prima-ry endpoint was 24-month change in femoral-neck BMD (g/cm²) analyzed by base-line-adjusted linear regression; secondary outcomes were lumbar spine and distal radius BMD, serum bone turnover markers (β-CTX-I, P1NP), health-related quality of life, and safety. Results: The primary analysis included participants with 24-month DXA (CalGo® n=29; placebo n=30). Femoral-neck BMD was maintained with CalGo® (+0.003 g/cm²; +0.4%) but declined with placebo (–0.017 g/cm²; –2.4%), yielding a significant base-line-adjusted between-group difference of +0.019 g/cm² (95% CI 0.001–0.038; p=0.044). Lumbar-spine loss was attenuated with CalGo® (–0.005 g/cm²; –0.3%) versus placebo (–0.028 g/cm²; –3.4%); the adjusted difference favored CalGo® (+0.026 g/cm²; p=0.058), and ≥1% spine gain was more likely with CalGo® (32.5% vs 11.4%; OR 3.61; p=0.043). No treatment effects were seen at the distal radius, in bone turnover markers, or in EQ-5D/EQ-VAS. CalGo® was well tolerated, with low adverse-event rates and no hepatic or renal safety signals. Conclusions: Over 24 months, CalGo® preserved femoral-neck BMD and attenuated lumbar-spine loss in osteopenic postmenopausal women, with a favorable safety profile.Keywords
All Related Versions
- Version 1, 2025-09-10, Preprints
- Published version: Biomedicines, 13 (11), 2616.
This publication has 18 references indexed in Scilit:
- Calcium Supplementation- Efficacy and SafetyCurrent Osteoporosis Reports, 2025
- High-Intensity Exercise and Geometric Indices of Hip Bone Strength in Postmenopausal Women on or off Bone Medication: The MEDEX-OP Randomised Controlled TrialCalcified Tissue International, 2022
- A look behind the scenes: the risk and pathogenesis of primary osteoporosisNature Reviews Rheumatology, 2015
- Acute and 3-month effects of microcrystalline hydroxyapatite, calcium citrate and calcium carbonate on serum calcium and markers of bone turnover: a randomised controlled trial in postmenopausal womenBritish Journal of Nutrition, 2014
- Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone massJournal of Bone and Mineral Research, 2011
- Excess mortality following hip fracture: a systematic epidemiological reviewOsteoporosis International, 2009
- Cortical and trabecular bone in the femoral neck both contribute to proximal femur failure load predictionOsteoporosis International, 2008
- Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysisThe Lancet, 2007
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- Stress distributions within the proximal femur during gait and falls: Implications for osteoporotic fractureOsteoporosis International, 1995